JP2018514193A5 - - Google Patents

Info

Publication number

JP2018514193A5

JP2018514193A5 JP2017549051A JP2017549051A JP2018514193A5 JP 2018514193 A5 JP2018514193 A5 JP 2018514193A5 JP 2017549051 A JP2017549051 A JP 2017549051A JP 2017549051 A JP2017549051 A JP 2017549051A JP 2018514193 A5 JP2018514193 A5 JP 2018514193A5

Authority

JP

Japan

Prior art keywords

seq

antibody

binding fragment

antigen

sequence

Prior art date

2016-03-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims description 79
• 239000000427 antigen Substances 0.000 claims description 74
• 102000036639 antigens Human genes 0.000 claims description 74
• 108091007433 antigens Proteins 0.000 claims description 74
• 241000725619 Dengue virus Species 0.000 claims description 35
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
• 150000001413 amino acids Chemical class 0.000 claims description 17
• 239000002245 particle Substances 0.000 claims description 17
• 102000003886 Glycoproteins Human genes 0.000 claims description 12
• 108090000288 Glycoproteins Proteins 0.000 claims description 12
• 150000007523 nucleic acids Chemical group 0.000 claims description 12
• 239000002773 nucleotide Substances 0.000 claims description 8
• 125000003729 nucleotide group Chemical group 0.000 claims description 8
• 206010012310 Dengue fever Diseases 0.000 claims description 6
• 208000025729 dengue disease Diseases 0.000 claims description 6
• 238000000034 method Methods 0.000 claims description 6
• 229960005486 vaccine Drugs 0.000 claims description 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• 108020004707 nucleic acids Proteins 0.000 claims description 4
• 102000039446 nucleic acids Human genes 0.000 claims description 4
• 101710204837 Envelope small membrane protein Proteins 0.000 claims description 3
• 101710145006 Lysis protein Proteins 0.000 claims description 3
• 238000012986 modification Methods 0.000 claims description 3
• 230000004048 modification Effects 0.000 claims description 3
• 208000001490 Dengue Diseases 0.000 claims description 2
• 102000009490 IgG Receptors Human genes 0.000 claims description 2
• 108010073807 IgG Receptors Proteins 0.000 claims description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
• 241000700605 Viruses Species 0.000 claims description 2
• 230000000295 complement effect Effects 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims description 2
• 230000001225 therapeutic effect Effects 0.000 claims description 2
• 238000002560 therapeutic procedure Methods 0.000 claims description 2
• 238000001727 in vivo Methods 0.000 description 4
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1